Consolidation has been a consistent theme in the pharmaceutical industry over the last few years and especially in 2019, with some deals setting new records at over $50 billion. We don’t expect these industry mergers and acquisitions to slow down any time soon as new drugs enter the market, blockbuster drugs reach patent expiration, and companies are placed under increased scrutiny to lower prices and cut costs.
For commercial teams, this landscape brings about immense top-down pressure to demonstrate results and increase efficiency. And those pressures don’t just affect big pharma. For big and small companies alike, teams must work quickly, part of which involves effective promotional and medical information review.